Drug Profile

Voclosporin - Aurinia Pharmaceuticals

Alternative Names: trans-ISA 247; trans-R 1524; ISA(TX)247; ISA-247; ISAtx 247; ISATx247; LUPKYNIS; Orelvo; R-1524; Voclera

Latest Information Update: 19 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Isotechnika
Developer Atrium Medical Corporation; Aurinia Pharmaceuticals; Isotechnika; Leiden University Medical Center; Otsuka Pharmaceutical; Paladin Labs
Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antivirals; Ciclosporins; Eye disorder therapies; Immunotherapies; Skin disorder therapies; Small molecules; Urologics; Vascular disorder therapies
Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Virus replication inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Lupus nephritis
New Molecular Entity Yes

Marketed Lupus nephritis
Phase II COVID 2019 infections; Focal segmental glomerulosclerosis
No development reported Nephrotic syndrome; Renal transplant rejection
Discontinued Coronary artery restenosis; Plaque psoriasis; Rheumatoid arthritis

10 Feb 2026 Aurinia Pharmaceuticals terminates a phase III trial in Lupus Nephritis (In Children, In adolescents) in USA, Mexico, Thailand, Japan, Colombia (PO) based on DSMB recommendation (NCT05288855)
04 Jul 2025 Aurinia Pharmaceuticals discontinues the phase III VOCAL-EXT trial for Lupus nephritis (Adjunctive treatment, In adolescents, In children) in USA, Colombia, Japan, Mexico, Thailand (PO, Capsule), due to the DSMB recommendation (NCT05962788)
18 Nov 2024 Updated efficacy data from the phase III AURORA 1 trial in Lupus nephritis released by Aurinia Pharmaceuticals

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com